These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24054532)

  • 1. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 2. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The price of prevention: what now for immunisation against meningococcus B?
    Moxon R; Snape MD
    Lancet; 2013 Aug; 382(9890):369-370. PubMed ID: 23911365
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunisation against meningococcus B.
    Head C
    Lancet; 2013 Sep; 382(9896):935. PubMed ID: 24034290
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunisation against meningococcus B.
    Rappuoli R
    Lancet; 2013 Sep; 382(9896):935-6. PubMed ID: 24034289
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities for meningococcal vaccination in the developing world.
    Shaker R; Fayad D; Dbaibo G
    Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is public meningococcal C vaccination the preferred value for money at cost-neutral?
    Gravatt L
    N Z Med J; 2013 Oct; 126(1384):123-5. PubMed ID: 24162638
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
    Andrews SM; Pollard AJ
    Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New meningococcal vaccines in the UK.
    Lloyd KE; Paul SP; Garg AK
    Community Pract; 2015 Nov; 88(11):28-30, 33. PubMed ID: 26749613
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bexsero, a novel vaccine against meningococcus].
    Lakos A; Torzsa P; Ferenci T
    Orv Hetil; 2016 Feb; 157(7):242-6. PubMed ID: 26853725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 18. [Meningococcus B vaccine: a new tool against invasive bacteric diseases].
    Carlino C; Zaratti L; Franco E
    Ig Sanita Pubbl; 2013; 69(3):363-75. PubMed ID: 23903040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine evaluation: lessons from a meningococcal B vaccine.
    Sarfatti A; Martinón-Torres F; Nadel S
    Arch Dis Child; 2015 Jun; 100(6):514-6. PubMed ID: 25670403
    [No Abstract]   [Full Text] [Related]  

  • 20. [Group B meningococcal invasive infections: an unresolved public health problem].
    Crisinel PA; Posfay-Barbe KM
    Rev Med Suisse; 2011 Feb; 7(283):447-50. PubMed ID: 21452513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.